Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine

7.项目摘要/摘要 该应用程序的目标是确定自然感染和/或 流感疫苗接种，可能适用于定义的其他传染病病原体的标志物 在RFA里。我们已经组建了一支由相关传染病组成的多学科团队 有权获得适当患者样本的专家、临床专家和化验专家 开发、鉴定和验证。我们将利用一个新发现的预测 来自哈特里实验室的签名；由Dekker和Davis小组开发的独特临床队列； 斯坦福大学人类免疫监测中心(HIMC)使用 Fluidigm、FACS和CyTOF；以及Wang和 乌茨实验室。虽然超出了我们的应用范围，但生物标志物签名和化验 这里开发的可用于研究其他感染源和疫苗策略 在这一RFA机制下提供资金。我们的三个具体目标将集中在验证、应用 以及此签名的翻译。具体目标1是验证一组生物标记物的能力 预测对流感疫苗接种的反应和从野生型流感病毒感染中恢复。 具体目标2将描述目标1中确定的生物途径，使用已建立的和 之前描述的患者队列，并比较现有的生物标记物数据集 可用。最后，《特定目标3》将开发一种快速、多重的检测转录本的方法。 使用巨磁阻(GMR)传感器，长期目标是构建一种能够 在分析点几分钟内测量多个转录本。我们的学习将提高我们的 了解应对流感和其他疾病所涉及的重要生物过程 病原体，并将提供临床上可获得的快速甚至实时的免疫指标 对患者和疫苗的评估。

7. Project Summary/Abstract The goal of this application is to identify predictive markers for outcomes of natural infection and/or vaccination with influenza, markers that are perhaps applicable to other infectious agents defined in the RFA. We have assembled a multi-disciplinary team composed of relevant infectious disease experts, clinical experts with access to appropriate patient samples, and experts in assay development, qualification, and validation. We will take advantage of a newly discovered predictive signature from the Khatri lab; unique clinical cohorts developed by the Dekker and Davis groups; Stanford’s Human Immune Monitoring Center (HIMC) for analysis of blood samples using Fluidigm, FACS and CyTOF; and expertise in multiplexed assay development by the Wang and Utz labs. Although beyond the scope of our application, the biomarker signature and the assays developed herein can be used to study other infectious agents and vaccine strategies that will be funded under this RFA mechanism. Our three specific aims will focus on the validation, application and translation of this signature. Specific Aim 1 is to validate a panel of biomarkers for their ability to predict response to influenza vaccination and recovery from wild-type influenza virus infection. Specific Aim 2 will characterize biological pathways identified in Aim 1 using well-established and previously described patient cohorts, and to compare the existing biomarker datasets that are available. Finally, Specific Aim 3 will develop a rapid, multiplexed assay for measuring transcripts using Giant MagnetoResistive (GMR) Sensors, with a long term goal to build a sensor capable of measuring multiple transcripts within minutes at point-of-assay. Our studies will enhance our understanding of the important biological processes involved in response to influenza and other pathogens, and will provide a clinically accessible immune metric for rapid or even real-time evaluation of patients and vaccines.